Abstract
The multiple sclerosis (MS) market has total global revenues of over $6bn in
2008. Those revenues will exceed $9bn during the second half of next decade,
our new study shows. The World Health Organization estimates that over 2.5
million people suffer from multiple sclerosis worldwide. The prevalence and
onset of MS in children and adults is expected to rise steadily. Global sales
for MS therapies will rise accordingly, due to epidemiological, healthcare and
commercial drivers. In this new market-based study - The Global Multiple
Sclerosis Market 2009-2024 - we show and explain those trends in detail. This
report will provide you with the analytical information that you need to
understand current trends and future directions in the MS market area, the
successful drugs being introduced and where the future successful growth of
the market lies.
The Global Multiple Sclerosis Market 2009-2024 commercially analyses both
leading and emergent treatments, with key companies and products discussed
comprehensively. In particular, we discuss prospects for the following MS
drugs:
- Tysabri
- Avonex
- Copaxone
- Betaferon
- Rebif.
Contemporary disease-modifying drugs for MS are administered intravenously,
intramuscularly or subcutaneously, typically with discomfort to patients. We
believe that orally-administered MS products will change the dynamics of the
market area significantly. But you must understand now the commercial
opportunities for those new agents and other exciting pipeline developments.
This report answers those important questions and others, such as how the
established MS products will fare competitively in the years ahead. Which will
remain the most profitable and how will they be affected by new competition.
Comprehensive Market Analysis
The Global Multiple Sclerosis Market 2009-2024 examines the market sector
critically through a comprehensive review of information sources, including
first-hand primary consultations with relevant experts. This report provides
detailed sales forecasts, discussions of pipeline developments and analyses of
important contemporary issues, especially relevant commercial drivers and
restraints. Sources used include gold-standard commercial databases, in-house
analytical tool, industry news, published reports, policy documents and
economic research. Importantly, visiongain applies rigorous financial
forecasting, qualitative analyses and the assessment of unmet needs. The
result is a comprehensive market- and industry-centred report with detailed
analysis and informed opinion.
Why you should buy the Global Multiple Sclerosis Market 2009-2024 By purchasing this report, you will receive the following benefits:
Predicted revenues, growth rates and other key metrics for the global MS drugs
market from 2009 to 2024 Predicted revenues, growth rates and other key
metrics for leading MS drugs worldwide from 2009 to 2024 Predicted revenues,
growth rates and other key metrics for MS drug sales in leading nations from
2009 to 2024 Expert opinions from original visiongain interviews, with full
interview transcripts - you will not find this information anywhere else
Discussion of hot pipeline developments and up-and-coming products Discussion
of forces that influence and characterise the market for MS treatments
worldwide:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats
Discussion of where the market is heading overall - both technologically and
commercially - from the present onwards.
Table of Contents
1 Executive Summary
- 1.1 Multiple Sclerosis Market Review
- 1.2 Aims, Scope and Format of the Report
2 Introduction to Multiple Sclerosis
- 2.1 The Biology of MS
- 2.2 The Disease
- 2.2.1 Symptoms of MS
- 2.2.2 Diagnosis of MS
- 2.3 Measuring MS
- 2.3.1 The Kurtzke Expanded Disability Status Scale (EDSS)
- 2.4 The Different Types of MS
- 2.4.1 Relapsing-Remitting MS
- 2.4.2 Secondary Progressive MS
- 2.4.3 Progressive Relapsing MS
- 2.4.4 Primary Progressive MS
- 2.4.5 Other Atypical Presentations
- 2.5 Causational Factors of MS
- 2.5.1 Genetic Factors
- 2.5.2 Infection
- 2.5.3 Environmental Factors and Less Supported Theories
- 2.6 World Demographics and Economic Costs of MS
- 2.7 Treatment Options
- 2.7.1 Alternative Treatments
- 2.7.2 Medical Approaches
- 2.8 Pharmacotherapy
- 2.8.1 Treatment of Acute Symptomatic Attack
- 2.8.2 Disease-Modifying Treatments
3 The Market for MS Drugs 2009-2024
- 3.1 MS Market Analysis
- 3.2 The Leading MS Drugs - Overall Sales Comparisons
- 3.3 Biogen' s Avonex was Top-Selling MS Drug - How will it Fare?
- 3.3.1 Avonex Sales from 2009 to 2024
- 3.3.2 Patent Expiry in Major Markets Will Impact on Revenues
- 3.3.3 How Will Increased Competition Affect Sales from 2010 Onwards?
- 3.4 Will Copaxone' s Revenues Increase Despite Competitive Threats?
- 3.4.1 Copaxone and Direct Competition
- 3.4.2 Will Product Development Increase Market Potential?
- 3.4.3 Competition Resulting from Newer Therapies and Patent Expiry -
What Effects on Sales?
- 3.5 Will Rebif' s Efficacy and Drug Delivery Lead to Market Dominance?
- 3.5.1 Will Novel Delivery Mechanism Drive Sales in the Retail Sector?
- 3.5.2 Rebif' s Sales During Forecast Period
- 3.6 Betaferon Faces Patent Expiry During the Forecast Period
- 3.6.1 Will Betaferon Be Competitive Enough in the Market?
- 3.7 Will Re-Launched Tysabri Generate Blockbuster Sales?
- 3.7.1 Two New PML Cases May Erode Sales
- 3.7.2 Tysabri (natalizumab) for Oncology
- 3.8 Prospects for the Oral MS Drug Market
- 3.9 MS Market Summary 2009-2024
4 The Market for MS Drugs in the Seven Major Markets, 2009-2024
- 4.1 MS Drugs in the Seven Major Markets: Analysis
- 4.2 MS Market in the US
- 4.2.1 Leading MS Products in the US Market
- 4.2.2 Market Drivers
- 4.2.3 Market Restraints
- 4.3 MS Market in Germany
- 4.3.1 Leading MS Products in the German Market
- 4.3.2 Market Drivers
- 4.3.3 Market Restraints
- 4.4 MS Market in France
- 4.4.1 Leading MS Products in the French Market
- 4.4.2 Market Drivers
- 4.4.3 Market Restraints
- 4.5 MS Market in Italy
- 4.5.1 Leading MS Products in the Italian Market
- 4.5.2 Market Drivers
- 4.5.3 Market Restraints
- 4.6 MS Market in Canada
- 4.6.1 Leading MS Products in the Canadian Market
- 4.6.2 Market Drivers
- 4.6.3 Market Restraints
- 4.7 MS Market in Spain
- 4.7.1 Leading MS Products in the Spanish Market
- 4.7.2 Market Drivers
- 4.7.3 Market Restraints
- 4.8 MS Market in the UK
- 4.8.1 Leading MS Products in the UK Market
- 4.8.2 Market Drivers
- 4.8.3 Market Restraints
5 An Analysis of Factors that Influence the Global MS Market
- 5.1 SWOT Analysis of the MS Market 2009-2024
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 The MS Market Has Opportunities for Continuing Growth
- 5.5 Entry of Oral MS Drugs Will Provide More-Accessible Treatment Options
- 5.6 Advances in Technology Likely to Bring Benefits to the Market
- 5.7 Comparative Studies - a Two-Edged Sword
- 5.8 Important Patient Sub-Populations: Potential for Companies to Increase
Market Leverage Through Product Differentiation
- 5.9 Concerns Over the High Price of Treatments - Who Yields the Power?
- 5.10 A Discussion of Generic Drugs in This Market - How Great is Their
Threat?
- 5.11 How Much Scope is There to Improve Safety and Tolerability in MS
Drugs?
6 Leading Companies in MS Therapy Development
- 6.1 Key Companies Delivering MS Therapies Highlighted
- 6.1.1 Biogen Idec and Elan Pharmaceuticals
- 6.1.2 Merck Serono
- 6.1.3 Bayer-Schering
- 6.1.4 Sanofi-Aventis and Teva
7 Pipeline Drugs for MS
- 7.1 MS Pipeline Drugs
- 7.2 The Potential Treatment Options in MS
- 7.2.1 Reducing Inflammatory Response
- 7.2.2 Managing Autoimmune Response
- 7.2.3 Manipulating the Permeability of the Blood-Brain Barrier
- 7.2.4 Inhibiting Demyelination
- 7.2.5 Protection Axons from Damage
- 7.2.6 Encouraging Remyelination
- 7.3 Drugs that Regulate Immune Response by Destroying Lymphocytes
- 7.3.1 Fingolimod (FTY720)
- 7.3.2 Mylinax (Oral Formulation)
- 7.3.3 Alemtuzumab
- 7.3.4 Rituximab
- 7.4 Drugs that Manage Immune Activity
- 7.4.1 Teriflunomide
- 7.4.2 Laquinimod
- 7.4.3 Daclizumab
- 7.4.4 MBP 8298
- 7.4.5 Integrin Inhibitors
- 7.5 Drugs that Reduce Inflammation
- 7.5.1 BG-12
- 7.5.2 MLN 1202
- 7.5.3 Ibudilast
- 7.6 MS Vaccines
- 7.6.1 Tovaxin
- 7.6.2 BHT-3009
- 7.7 Drugs to Improve Nerve Function
- 7.7.1 Fampridine-SR
- 7.7.2 Lamotrigine
- 7.8 Pfizer' s Lipitor (atorvastin) and Other Statins
- 7.9 GW Sativex Investigational Cannabis-Based Treatment for MS 7.10 An
"Oral Drug Revolution" in MS Treatment - a Possibility?
- 7.11 MS Pipeline Shows Short- and Long-Term Potential
- 7.12 The Future of MS Treatments
- 7.12.1 Stem Cell Therapy
- 7.12.2 Thyroid Hormone has Treatment Potential
8 Experts' Views
- 8.1 Interview with Dr. Rosie Jones from Bristol General Hospital, MS
Research Unit, UK
- 8.1.1 Introduction
- 8.1.2 Understanding MS
- 8.1.3 On Disease-Modifying Treatments
- 8.1.4 On Oral Drugs
- 8.1.5 On the Problems of Long-Term Treatments
- 8.1.6 On Natalizumab (Tysabri) and Progressive Multifocal
Leukoencephalopathy (PML)
- 8.1.7 On Alternative Treatments
- 8.1.8 On Medical Marijuana Use
- 8.1.9 The Future of MS Treatments
- 8.2 Interview with Dr Johan Luthman (Merck Serono)
- 8.2.1 On Understanding the Disease and its Treatment
- 8.2.2 On Unmet Needs for MS Therapy
- 8.2.3 On Current Treatment Options
- 8.2.4 On Medical Marijuana Use
- 8.2.5 On Oral Drugs
- 8.2.6 On Future Treatment Possibilities
- 8.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically
Concerning Stem Cell Potential in MS
- 8.3.1 On Stem Cell Media Coverage
- 8.3.2 On the Therapeutic and Curative Potential of Stem Cells for
Neurological Disorders
- 8.3.3 On the Treatment of Neurological Disorders
- 8.3.4 On Stem Cell Treatment of MS - Viability, Curative Power,
Treatment Strategy and Results
- 8.3.5 On the Timeframe for Marketable Stem Cell Treatment Options
- 8.4 Concluding Thoughts
- 8.4.1 Concerning Symptom Management
- 8.4.2 Concerning Current Treatments and Patient Sub-Groups
- 8.4.3 Concerning Oral Drugs
- 8.4.4 Concerning Stem Cell Treatment
9 Conclusions
- 9.1 The MS Market Will Achieve Continued Growth
- 9.2 Great Scope for an Oral MS Drug to Enter the Market
- 9.3 Major Players in the MS Market
- 9.4 Market Drivers
- 9.5 Market Restraints
- 9.6 MS Market - Overview
List of Tables
- Table 2.1 The Kurtzke Expanded Disability Scale
- Table 3.1 The Total Market for MS Drugs: Revenue ($m) Forecast, 2009-2024
- Table 3.2 Revenues ($m), 7-Year CAGR (%) and Market Share (%) for the
Leading MS Drugs, 2007 & 2014
- Table 3.3 Top 5 MS Products Rank Comparison, 2007 and 2024
- Table 4.1 MS Drugs: Revenue ($m) Forecast in the Seven Major Markets,
2009-2024
- Table 4.2 The Leading MS Drugs in the US Market, 2007
- Table 4.3 The Leading MS Drugs in the German Market, 2007
- Table 4.4 The Leading MS Drugs in the French Market, 2007
- Table 4.5 The Leading MS Drugs in the Italian Market, 2007
- Table 4.6 The Leading MS Drugs in the Canadian Market, 2007
- Table 4.7 The Leading MS Drugs in the Spanish Market, 2007
- Table 4.8 The Leading MS Drugs in the UK Market, 2007
- Table 5.1 A SWOT Chart for the MS Market, 2009-2024
- Table 6.1 Top 5 Companies in the MS Market, 2007
- Table 7.1 MS Pipeline Drugs: Phase II and Beyond, 2008
List of Figures
- Figure 3.1 The Total MS Market: Revenue ($m) Forecast, 2009-2024
- Figure 3.2 The Leading MS Drugs: Market Revenue ($m) Forecast, 2009-2024
- Figure 3.3 Leading MS Drugs: Revenue ($m) by Sector, 2007
- Figure 3.4 Leading MS Drugs: Market Share (%), 2007
- Figure 3.5 Leading MS Drugs: Market Share (%), 2014
- Figure 3.6 Avonex Revenue ($m) Forecast 2009-2024
- Figure 3.7 Copaxone Revenue ($m) Forecast 2009-2024
- Figure 3.8 Rebif Revenue ($m) Forecast 2009-2024
- Figure 3.9 Betaferon Revenue ($m) Forecast 2009-2024
- Figure 3.10 Tysabri Revenue ($m) Forecast 2009-2024
- Figure 4.1 The US MS Market Revenue ($m) Forecast, 2009-2024
- Figure 4.2 The German MS Market Revenue ($m) Forecast, 2009-2024
- Figure 4.3 The French MS Market Revenue ($m) Forecast, 2009-2024
- Figure 4.4 The Italian MS Market Revenue ($m) Forecast, 2009-2024
- Figure 4.5 The Canadian MS Market Revenue ($m) Forecast, 2009-2024
- Figure 4.6 The Spanish MS Market Revenue ($m) Forecast, 2009-2024
- Figure 4.7 The UK MS Market Revenue ($m) Forecast, 2009-2024
- Figure 9.1 Total Revenues ($m) for MS Drugs, 2009-2024
Companies Mentioned in this Report
- Active Biotech
- Acorda Therapeutics
- Aegera Idera
- Allergan
- Antisense Therapeutics
- Apitope
- Argyll Biotechnologies
- Asphelia
- Bayer-Schering
- Bayhill Therapeutics
- Berlex Laboratories
- Biogen Idec
- BioMS
- BioPartners
- BTG
- Elan Pharmaceuticals
- Eli Lilly
- Fornix
- GemacBio
- Genentech
- GlaxoSmithKline
- GW Pharmaceuticals
- IMS
- Indevus
- InterMune
- Isis
- Manhattan
- Medarex
- MediciNova
- Merck KGaA
- Merck Serono
- Millennium
- Mitsubishi Tanabe Pharma
- Momenta Pharmaceuticals
- Mylan
- Natco Pharmaceuticals
- Neuren
- Novartis
- Opexa
- Orchestra Therapeutics
- Otsuka Pharmaceuticals
- PDL BioPharma
- Pfizer
- ReceptoPharm
- Rentschler
- Roche
- Sanofi-Aventis
- Teva
- Transition
- UCB
|
相關報告
|
